Key clinical point: A retrospective study suggests administrative data may improve the accuracy and lower costs of oncology clinical trial economic analyses.
Major finding: Incremental cost-effectiveness ratio (ICER) measures were comparable with the use of administrative data versus trial data alone ($164,378 vs. $211,128 per QALY added up to last contact).
Study details: A retrospective analysis of 572 patients with previously treated metastatic colorectal cancer.
Disclosures: The study was funded by ICES and Queen’s University. The authors reported financial affiliations with Amgen, Janssen, Novartis, and UpToDate.
Hanna TP et al. J Oncol Pract. 2019 Jul 15. doi: 10.1200/JOP.18.00691.